Elusys' Anthrax Drug OK'd; US Contract Already In Hand
This article was originally published in Scrip
Executive Summary
Should the US ever face another anthrax attack, like in 2001, when someone sent Bacillus anthracis spores through the US mail, infecting 11 people, five of whom died, there's another drug approved by the FDA to address the situation – Pine Brook, NJ-based Elusys Therapeutics Inc.'s Anthim (obiltoxaximab).